Welcome to our dedicated page for Cabbacis news (Ticker: CABI), a resource for investors and traders seeking the latest updates and insights on Cabbacis stock.
Cabbacis Inc (OTCQB: CABI) is a U.S. federally licensed tobacco-product manufacturer focused on harm-reduction products developed under its iBlend™ brand. The Cabbacis news feed on Stock Titan brings together company press releases and market updates that explain how the business is progressing with reduced-nicotine cigarettes and vaporizer pods that are predominately tobacco and include hemp.
In its news, Cabbacis highlights developments such as clinical trial results for its patented iBlend™ reduced-nicotine cigarettes, which the company reports were highly rated for satisfaction and significantly reduced cravings for usual brand cigarettes. Updates also cover new patents for vaporizer pods that blend reconstituted tobacco and hemp, expansion of its global intellectual property portfolio, and descriptions of how these patents apply across major tobacco markets.
Investors following CABI news can also read about capital markets milestones, including qualification of Regulation A (Tier 2) offerings, use of proceeds for product development and FDA Premarket Tobacco Product Applications, and the company’s DTC eligibility and OTCQB trading status. Additional releases describe participation in investor conferences, engagement of investor relations advisors, and commentary from management on the commercialization pathway for iBlend™ products.
This page aggregates these announcements so readers can review how Cabbacis presents its harm-reduction strategy, regulatory plans, patent activity and financing efforts over time. For those tracking the evolution of reduced-nicotine tobacco and hemp-based products, the CABI news stream offers direct access to the company’s own descriptions of its progress and objectives.
Cabbacis (OTCQB: CABI) announced management will present at the Noble Emerging Growth Virtual Equity Conference on February 4-5, 2026. CEO Joseph Pandolfino will present on Feb 4, 2026 at 11:00 a.m. ET and hold one-on-one investor meetings. Registration is required and the presentation is webcast.
The company said its $7.5 million Regulation A+ offering is progressing and highlighted a global patent portfolio of 36 issued patents (including 8 U.S.) for its iBlend brand as it advances product development and planned international rollout later in 2026.
Cabbacis (OTCQB: CABI) issued a shareholder letter outlining 2025 milestones and 2026 plans for its iBlend very-low-nicotine tobacco products. Highlights include positive pilot clinical results, a global patent portfolio of 36 patents, a clean balance sheet, a SEC-qualified Regulation A+ offering, and a planned PMTA filing mid-2026.
The company targets limited international rollouts in late 2026, two follow-up behavioral studies in early 2026, and a U.S. PMTA review timeline the company anticipates could be about one year.
Cabbacis (OTCQB: CABI) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 12,527,346 for vaporizer pods combining reconstituted tobacco and reconstituted hemp (CBGA-most abundant); the patent expires January 1, 2039 and includes seven claims. The company noted this patent complements three previously issued U.S. patents (10,777,091; 10,973,255; 12,349,724) and international patents, and said its products are patented across more than 30 countries.
Cabbacis (OTCQB: CABI) announced a $7.5 million Regulation A offering and will host an investor webinar on January 22, 2026 at 11:30 AM ET. CEO Joseph Pandolfino will discuss investment details, the development and commercialization of the company’s patented iBlend™ cigarettes and vaporizer pods (very-low-nicotine tobacco plus hemp), the company’s FDA path for U.S. commercialization, and an international rollout expected later in 2026 to generate early revenue and brand validation. The webinar replay will be emailed to registrants; investors are not required to be accredited.
Summary not available.
Cabbacis (OTCQB: CABI), a tobacco-product manufacturer, released its First Half 2025 corporate update. The company reported a net loss of $735,560 ($0.12 per share), compared to a loss of $299,480 ($0.05 per share) in H1 2024, with no revenue in both periods.
Key developments include successful clinical trials of their iBlend™ cigarettes, expansion of their patent portfolio to 35 issued patents, and the launch of a $7.5 million Regulation A offering. The company's clinical trials demonstrated high satisfaction rates and reduced cravings, with their products containing approximately 95% less nicotine than mainstream brands.
Cabbacis plans to file its first PMTA around January 2026 and is exploring international licensing opportunities while awaiting FDA review.
Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer, will participate in the upcoming Q3 Virtual Investor Summit on September 16-17, 2025. CEO Joseph Pandolfino will present on Tuesday, September 16, at 10:00 a.m. Eastern time and conduct one-on-one meetings with institutional investors.
The company will discuss recent achievements, including the granting of U.S. patent No. 12,349,724 for their vaporizer pods and the qualification of their Regulation A Tier 2 offering. These developments support Cabbacis's commercialization strategy in the harm-reduction tobacco products sector under their iBlend™ brand.
Cabbacis (OTCQB: CABI), a federally-licensed tobacco manufacturer, has engaged MZ Group to lead its strategic investor relations and financial communications program. The company is developing harm-reduction products under the iBlend™ brand for the $1.1 trillion global tobacco market.
Cabbacis recently completed a successful pilot clinical trial testing four types of reduced-nicotine tobacco cigarettes. The company holds 35 issued product patents, including 7 in the U.S., and operates an established production facility. Their iBlend™ products, combining reduced-nicotine tobacco and hemp, achieve a 95% reduction in nicotine compared to popular cigarette brands, positioning them favorably for the FDA's proposed nicotine cap regulation.
The company plans to file its first FDA Premarket Tobacco Product Application (PMTA) in late 2025 while simultaneously pursuing international market opportunities.
Cabbacis (OTCQB: CABI) has been granted U.S. Patent No. 12,349,724 for vaporizer pods, expanding its intellectual property portfolio to 31 countries. The patent, valid until July 2038, covers pods containing blends of conventional or reduced-nicotine reconstituted tobacco with hemp for oral electronic vaporizers.
The company's iBlend™ product line features reduced-nicotine vaporizer pods and cigarettes containing 95% less nicotine than conventional brands. These products are designed to help users transition to less harmful tobacco alternatives. The patent portfolio now includes protection in major markets including the United States, China, Europe, Brazil, and Japan.
Cabbacis (OTCQB: CABI) has announced positive clinical trial results for its iBlend™ cigarettes, demonstrating significant efficacy in reducing cravings for regular cigarettes. The trial, conducted by Rose Research Center, tested four types of reduced-nicotine cigarettes on 16 smokers, including three variants with different hemp concentrations (5%, 10%, and 20%) and one without hemp.
Key findings revealed that all iBlend™ variants achieved higher satisfaction ratings on the standardized mCEQ questionnaire compared to other 95% reduced-nicotine cigarettes. Notably, the 20% hemp variant showed statistically significant reduction in exhaled carbon monoxide levels. The study supports Cabbacis's strategy to develop FDA-compliant products ahead of potential regulations requiring ~95% nicotine reduction in U.S. cigarettes.
FAQ
What is the current stock price of Cabbacis (CABI)?
